These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33628334)

  • 1. Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers.
    Zhao Y; Chen K; Ramia N; Sahu S; Kumar A; Naylor ML; Zhu L; Naik H; Butts CL
    Ther Adv Neurol Disord; 2021; 14():1756286420975227. PubMed ID: 33628334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon β-1a phase 1 study.
    Zhao Y; Mokliatchouk O; Ramia NF; Naylor ML; Butts CL
    Med; 2022 Sep; 3(9):612-621.e3. PubMed ID: 35853458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
    Hu X; Shang S; Nestorov I; Hasan J; Seddighzadeh A; Dawson K; Sperling B; Werneburg B
    Br J Clin Pharmacol; 2016 Aug; 82(2):380-8. PubMed ID: 27060836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
    Hu X; Cui Y; White J; Zhu Y; Deykin A; Nestorov I; Hung S
    Br J Clin Pharmacol; 2015 Mar; 79(3):514-22. PubMed ID: 25265472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.
    Kolb-Mäurer A; Sunderkötter C; Kukowski B; Meuth SG;
    BMC Neurol; 2019 Jun; 19(1):130. PubMed ID: 31202258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.
    Hendin B; Naismith RT; Wray SE; Huang D; Dong Q; Livingston T; Jones DL; Watson C; Jhaveri M
    Patient Prefer Adherence; 2018; 12():1289-1297. PubMed ID: 30050291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in magnetic resonance imaging T2 burden of disease in patients with relapsing-remitting multiple sclerosis: analysis of 48-week data from the EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) study.
    Traboulsee A; Al-Sabbagh A; Bennett R; Chang P; Li DK; ;
    BMC Neurol; 2008 Apr; 8():11. PubMed ID: 18426595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matching-adjusted comparisons demonstrate better clinical outcomes with SC peginterferon beta-1a every two weeks than with SC interferon beta-1a three times per week.
    Coyle PK; Shang S; Xiao Z; Dong Q; Castrillo-Viguera C
    Mult Scler Relat Disord; 2018 May; 22():134-138. PubMed ID: 29679749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept.
    Sweetser MT; Woodworth J; Swan S; Ticho B
    Dermatol Online J; 2006 Mar; 12(3):1. PubMed ID: 16638415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative Bioavailability Study of Midazolam Intramuscularly Administered with the Needle-Free Auto-Injector ZENEO
    Lacombe O; Pletan Y; Grouin JM; Brennan A; Giré O
    Neurol Ther; 2024 Aug; 13(4):1155-1172. PubMed ID: 38806873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
    Newsome SD; Mokliatchouk O; Castrillo-Viguera C; Naylor ML
    Mult Scler Relat Disord; 2020 May; 40():101954. PubMed ID: 32078948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
    Beer K; Müller M; Hew-Winzeler AM; Bont A; Maire P; You X; Foulds P; Mårlind J; Curtius D
    BMC Neurol; 2011 Nov; 11():144. PubMed ID: 22074056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.
    Hang Y; Hu X; Zhang J; Liu S; Deykin A; Nestorov I
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):371-83. PubMed ID: 27299457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
    Newsome SD; Kieseier BC; Liu S; You X; Kinter E; Hung S; Sperling B
    Ther Adv Neurol Disord; 2017 Jan; 10(1):41-50. PubMed ID: 28450894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.